董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| George Magrath | 男 | Chief Executive Officer and Director | 42 | 149.34万美元 | 174.44 | 2026-04-20 |
| Sean Ainsworth | 男 | Independent Director | 58 | 21.01万美元 | 55.52 | 2026-04-20 |
| Susan K. Benton | 女 | Independent Director | 61 | 18.01万美元 | 43.39 | 2026-04-20 |
| Benjamin R. Yerxa | 男 | Director and President | 60 | 未披露 | 9.44 | 2026-04-20 |
| Jean Bennett | 女 | Independent Director | 71 | 16.85万美元 | 37.19 | 2026-04-20 |
| Adrienne Graves | 女 | Independent Director | 72 | 17.14万美元 | 24.04 | 2026-04-20 |
| James S. Manuso | 男 | Independent Director | 77 | 18.89万美元 | 55.09 | 2026-04-20 |
| Richard Rodgers | 男 | Independent Director | 60 | 18.95万美元 | 52.34 | 2026-04-20 |
| Cam Gallagher | 男 | Independent Chairman of the Board | 56 | 29.60万美元 | 301.66 | 2026-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Gagnon | 男 | Chief Financial Officer | 52 | 未披露 | 未持股 | 2026-04-20 |
| George Magrath | 男 | Chief Executive Officer and Director | 42 | 149.34万美元 | 174.44 | 2026-04-20 |
| Joseph Schachle | 男 | Chief Operating Officer | 61 | 71.84万美元 | 23.47 | 2026-04-20 |
| Amy Rabourn | 女 | Head of Financial Quality Assurance | 46 | 未披露 | 未持股 | 2026-04-20 |
| Benjamin R. Yerxa | 男 | Director and President | 60 | 未披露 | 9.44 | 2026-04-20 |
| Ashwath Jayagopal | 男 | Chief Scientific and Development Officer | 44 | 76.48万美元 | 21.16 | 2026-04-20 |
董事简历
中英对照 | 中文 | 英文- George Magrath
-
George Magrath，自2023年11月起担任Opus Genetics，Inc.首席执行官。Magrath博士此前担任Lexitas Pharmaceutical Services，Inc.（Lexitas）的首席执行官，他在2021年2月至2023年9月期间担任该职位，领导该公司从35名员工增长到超过200名员工，并监督公司的出售。随后，Magrath博士在2023年9月至2023年10月期间担任Lexitas的顾问。在担任这些职务之前，他曾于2020年8月至2021年1月在Lexitas担任首席医疗官。Magrath博士此前还曾于2015年8月至2020年8月担任Hovione Pharmaceuticals，LLC的医疗总监。Magrath博士于2021年8月至2023年9月担任Lexitas的董事会成员，并于2022年3月至2023年10月担任Line 6 Biotechnology，Inc.的科学顾问委员会成员，并于2019年11月至2023年1月担任ONO Pharmaceutical Co.，Ltd.的科学顾问委员会成员。他是Implicit Bioscience的董事会观察员（自2022年起）和Foundation Fighting Blindness Translational Research Acceleration Program的顾问委员会成员（自2022年起）。Magrath博士已完成卡内基梅隆大学和美国国家公司董事协会网络安全监督学CERT证书的要求。Magrath博士获得了Citadel的工商管理硕士学位、南卡罗来纳医科大学的医学博士学位、约翰霍普金斯大学的应用经济学硕士学位和克莱姆森大学的生物化学学士学位。Magrath博士还是两项授权专利的共同发明人，撰写了超过25篇同行评审文章。Magrath博士还曾于2016年至2017年在Edison Investment Research担任股票分析师。
George Magrath,has served as Opus Genetics, Inc. Chief Executive Officer since November 2023. Dr. Magrath was previously Chief Executive Officer of Lexitas Pharmaceutical Services, Inc. (Lexitas), a position he served in from February 2021 through September 2023, leading the company's growth from 35 to over 200 employees and overseeing the sale of the company. Dr. Magrath then served as a consultant to Lexitas from September 2023 through October 2023. Prior to serving in these roles, he served with Lexitas as its Chief Medical Officer from August 2020 to January 2021. Dr. Magrath has also previously served as medical director at Hovione Pharmaceuticals, LLC from August 2015 to August 2020. Dr. Magrath served on the board of directors of Lexitas from August 2021 through September 2023 and as a scientific advisory board member of Line 6 Biotechnology, Inc. from March 2022 to October 2023 and ONO Pharmaceutical Co., Ltd. from November 2019 to January 2023. He is a board observer of Implicit Bioscience (since 2022) and on the advisory board of Foundation Fighting Blindness Translational Research Acceleration Program (since 2022). Dr. Magrath has completed the requirements for the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University and the National Association of Corporate Directors. Dr. Magrath earned his M.B.A. from The Citadel, his M.D. from Medical University of South Carolina, his M.S. in Applied Economics from Johns Hopkins University and his B.S. in Biological Chemistry from Clemson University. Dr. Magrath is also a co-inventor on two granted patents and has authored over 25 peer-reviewed articles. Dr. Magrath also worked as an equity analyst at Edison Investment Research from 2016 to 2017. - George Magrath，自2023年11月起担任Opus Genetics，Inc.首席执行官。Magrath博士此前担任Lexitas Pharmaceutical Services，Inc.（Lexitas）的首席执行官，他在2021年2月至2023年9月期间担任该职位，领导该公司从35名员工增长到超过200名员工，并监督公司的出售。随后，Magrath博士在2023年9月至2023年10月期间担任Lexitas的顾问。在担任这些职务之前，他曾于2020年8月至2021年1月在Lexitas担任首席医疗官。Magrath博士此前还曾于2015年8月至2020年8月担任Hovione Pharmaceuticals，LLC的医疗总监。Magrath博士于2021年8月至2023年9月担任Lexitas的董事会成员，并于2022年3月至2023年10月担任Line 6 Biotechnology，Inc.的科学顾问委员会成员，并于2019年11月至2023年1月担任ONO Pharmaceutical Co.，Ltd.的科学顾问委员会成员。他是Implicit Bioscience的董事会观察员（自2022年起）和Foundation Fighting Blindness Translational Research Acceleration Program的顾问委员会成员（自2022年起）。Magrath博士已完成卡内基梅隆大学和美国国家公司董事协会网络安全监督学CERT证书的要求。Magrath博士获得了Citadel的工商管理硕士学位、南卡罗来纳医科大学的医学博士学位、约翰霍普金斯大学的应用经济学硕士学位和克莱姆森大学的生物化学学士学位。Magrath博士还是两项授权专利的共同发明人，撰写了超过25篇同行评审文章。Magrath博士还曾于2016年至2017年在Edison Investment Research担任股票分析师。
- George Magrath,has served as Opus Genetics, Inc. Chief Executive Officer since November 2023. Dr. Magrath was previously Chief Executive Officer of Lexitas Pharmaceutical Services, Inc. (Lexitas), a position he served in from February 2021 through September 2023, leading the company's growth from 35 to over 200 employees and overseeing the sale of the company. Dr. Magrath then served as a consultant to Lexitas from September 2023 through October 2023. Prior to serving in these roles, he served with Lexitas as its Chief Medical Officer from August 2020 to January 2021. Dr. Magrath has also previously served as medical director at Hovione Pharmaceuticals, LLC from August 2015 to August 2020. Dr. Magrath served on the board of directors of Lexitas from August 2021 through September 2023 and as a scientific advisory board member of Line 6 Biotechnology, Inc. from March 2022 to October 2023 and ONO Pharmaceutical Co., Ltd. from November 2019 to January 2023. He is a board observer of Implicit Bioscience (since 2022) and on the advisory board of Foundation Fighting Blindness Translational Research Acceleration Program (since 2022). Dr. Magrath has completed the requirements for the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University and the National Association of Corporate Directors. Dr. Magrath earned his M.B.A. from The Citadel, his M.D. from Medical University of South Carolina, his M.S. in Applied Economics from Johns Hopkins University and his B.S. in Biological Chemistry from Clemson University. Dr. Magrath is also a co-inventor on two granted patents and has authored over 25 peer-reviewed articles. Dr. Magrath also worked as an equity analyst at Edison Investment Research from 2016 to 2017.
- Sean Ainsworth
-
肖恩·安斯沃思（Sean Ainsworth）曾担任细胞治疗公司Immusoft Corporation的首席执行官兼董事会主席。在担任这一职务期间，Ainsworth先生在Immusoft Corporation和武田制药之间建立了战略联盟。2021年，Ainsworth先生与他人共同创立了一家眼部基因治疗公司Ray Therapeutics，他担任该公司的董事会主席。此前在2009年，他创立了RetroSense Therapeutics LLC，这是一家眼部基因治疗公司，Ainsworth先生担任首席执行官和董事长，该公司于2016年被Allergan收购。2004年至2012年，Ainsworth先生担任Ainsworth BioConsulting的负责人。2006年，Ainsworth先生与他人共同创立了Compendia BioScience，Inc.，该公司随后被Life Technologies收购。2004年至2012年，Ainsworth先生担任生命科学和企业家社区客户的顾问，负责与许可、战略和业务规划相关的事务。他的其他专业经历包括医学生物学研究所的研究、Kantar Health的企业发展咨询、东京Koyama and Associates的知识产权职位以及Mattson Jack Group的国际企业发展咨询，以及GeneVivo，LLC的首席执行官。Ainsworth先生于1996年获得加州大学圣地亚哥分校的微生物学学士学位，并于2002年获得圣路易斯华盛顿大学的工商管理硕士学位。
Sean Ainsworth,has been Chief Executive Officer and Chairman of the board at Immusoft Corporation, a cell therapy company. In this role, Mr. Ainsworth established a strategic alliance between Immusoft Corporation and Takeda Pharmaceuticals. In 2021, Mr. Ainsworth co-founded Ray Therapeutics, an ocular gene therapy company, for which he is chairman of its board. Previously, in 2009, he founded RetroSense Therapeutics LLC, an ocular gene therapeutic company for which Mr. Ainsworth served as Chief Executive Officer and Chairman, which was acquired by Allergan in 2016. From 2004 to 2012, Mr. Ainsworth served as Principal at Ainsworth BioConsulting. In 2006, Mr. Ainsworth co-founded Compendia BioScience, Inc., which was subsequently acquired by Life Technologies. From 2004 to 2012, Mr. Ainsworth served as an advisor to clients in the life sciences and entrepreneurial community on matters related to licensing, strategy and business planning. His other professional experience includes research at Medical Biology Institute, corporate development consulting at Kantar Health, intellectual property roles at Koyama and Associates in Tokyo and international corporate development consulting at the Mattson Jack Group, and CEO at GeneVivo, LLC. Mr. Ainsworth holds a B.S. in Microbiology from University of California, San Diego, in 1996 and an M.B.A. from Washington University in St. Louis in 2002. - 肖恩·安斯沃思（Sean Ainsworth）曾担任细胞治疗公司Immusoft Corporation的首席执行官兼董事会主席。在担任这一职务期间，Ainsworth先生在Immusoft Corporation和武田制药之间建立了战略联盟。2021年，Ainsworth先生与他人共同创立了一家眼部基因治疗公司Ray Therapeutics，他担任该公司的董事会主席。此前在2009年，他创立了RetroSense Therapeutics LLC，这是一家眼部基因治疗公司，Ainsworth先生担任首席执行官和董事长，该公司于2016年被Allergan收购。2004年至2012年，Ainsworth先生担任Ainsworth BioConsulting的负责人。2006年，Ainsworth先生与他人共同创立了Compendia BioScience，Inc.，该公司随后被Life Technologies收购。2004年至2012年，Ainsworth先生担任生命科学和企业家社区客户的顾问，负责与许可、战略和业务规划相关的事务。他的其他专业经历包括医学生物学研究所的研究、Kantar Health的企业发展咨询、东京Koyama and Associates的知识产权职位以及Mattson Jack Group的国际企业发展咨询，以及GeneVivo，LLC的首席执行官。Ainsworth先生于1996年获得加州大学圣地亚哥分校的微生物学学士学位，并于2002年获得圣路易斯华盛顿大学的工商管理硕士学位。
- Sean Ainsworth,has been Chief Executive Officer and Chairman of the board at Immusoft Corporation, a cell therapy company. In this role, Mr. Ainsworth established a strategic alliance between Immusoft Corporation and Takeda Pharmaceuticals. In 2021, Mr. Ainsworth co-founded Ray Therapeutics, an ocular gene therapy company, for which he is chairman of its board. Previously, in 2009, he founded RetroSense Therapeutics LLC, an ocular gene therapeutic company for which Mr. Ainsworth served as Chief Executive Officer and Chairman, which was acquired by Allergan in 2016. From 2004 to 2012, Mr. Ainsworth served as Principal at Ainsworth BioConsulting. In 2006, Mr. Ainsworth co-founded Compendia BioScience, Inc., which was subsequently acquired by Life Technologies. From 2004 to 2012, Mr. Ainsworth served as an advisor to clients in the life sciences and entrepreneurial community on matters related to licensing, strategy and business planning. His other professional experience includes research at Medical Biology Institute, corporate development consulting at Kantar Health, intellectual property roles at Koyama and Associates in Tokyo and international corporate development consulting at the Mattson Jack Group, and CEO at GeneVivo, LLC. Mr. Ainsworth holds a B.S. in Microbiology from University of California, San Diego, in 1996 and an M.B.A. from Washington University in St. Louis in 2002.
- Susan K. Benton
-
Susan K. Benton担任Thea Pharma，Inc.（Thea）的总裁，该公司是领先的独立眼科制药公司Thea Laboratories的全资子公司，她自2019年8月起担任该职位。Benton女士还在两家私营眼科公司的董事会任职：Tarsius Pharma Ltd.（自2019年3月起）和Ripple Therapeutics（自2022年3月起）。从2015年4月到2019年7月，她曾在Shire，Inc.（Shire）担任多个关键领导职位，包括眼科并购主管，并在扩大其眼科管道方面发挥了重要作用。作为Shire新产品的负责人，她领导了眼科创新委员会，该委员会塑造并执行了特许经营的增长战略。在加入Shire之前，Benton女士曾于2011年9月至2013年9月在Bausch + Lomb制药（B + L）担任全球业务发展领导职务，她和企业发展团队在三年内处理了十多笔交易。她是一家眼科初创公司Sirion Therapeutics，Inc.的联合创始人和首席商务官，她推出并监督了Durezol的商业化和Zirgan之前分别出售给了爱尔康和B + L。Benton女士于1995年3月在B + L开始了她的眼科职业生涯，在那里她担任了领导职务，担任多元化产品主管和专业销售副总裁。在她任职期间，她建立并配备了一支由75名销售专业人员组成的团队，并推出了B + L首个品牌产品Lotemax和Alrex，除了Optivar通过与Muro Pharmaceutical的共同推广。她还担任过十几家初创型眼科企业的战略顾问。她在眼科之外的经验包括担任强生糖尿病专营权LifeScan的消费者和专业销售副总裁，以及在赛诺菲巴斯德疫苗业务中担任高级经理职务。本顿女士获得了南佛罗里达大学的工商管理硕士学位和穆伦伯格学院的生物学学士学位。
Susan K. Benton,serves as the President for Thea Pharma, Inc. (Thea), a wholly-owned subsidiary of Thea Laboratories, a leading independent ophthalmic pharmaceutical company, a position she has held since August 2019. Ms. Benton also serves on the boards of two privately held ophthalmic companies: Tarsius Pharma Ltd. (since March 2019) and Ripple Therapeutics (since March 2022). From April 2015 through July 2019, she served in a number of key leadership positions at Shire, Inc. (Shire), including Head of M&A for Ophthalmology, and played an instrumental role in the expansion of its ophthalmic pipeline. As the Head of New Products at Shire, she led the Ophthalmic Innovation Committee that shaped and executed the growth strategy for the franchise. Before joining Shire, Ms. Benton served in a leadership capacity in Global Business Development for Bausch + Lomb Pharmaceuticals (B+L) from September 2011 through September 2013, where she and the Corporate Development team transacted over ten deals in three years. She was a co-Founder and Chief Commercial Officer for an ophthalmic start-up, Sirion Therapeutics, Inc., and she launched and oversaw the commercialization of Durezol and Zirgan before they were sold to Alcon and B+L, respectively. Ms. Benton began her ophthalmic career at B+L in March 1995, where she assumed leadership roles as the Head of Diversified Products and the VP of Professional Sales. During her tenure, she built and staffed a team of 75 sales professionals and she launched B+L's first ever branded products, Lotemax and Alrex, in addition to Optivar through a co-promote with Muro Pharmaceutical. She has also served as a strategic consultant for more than a dozen start-up ophthalmic companies. Her experience outside of ophthalmology includes roles as the VP of Consumer and Professional Sales for Johnson & Johnson's diabetes franchise, LifeScan, and senior manager roles in Sanofi Pasteur's vaccine business. Ms. Benton earned her M.B.A from the University of South Florida and a B.S. in Biology from Muhlenberg College. - Susan K. Benton担任Thea Pharma，Inc.（Thea）的总裁，该公司是领先的独立眼科制药公司Thea Laboratories的全资子公司，她自2019年8月起担任该职位。Benton女士还在两家私营眼科公司的董事会任职：Tarsius Pharma Ltd.（自2019年3月起）和Ripple Therapeutics（自2022年3月起）。从2015年4月到2019年7月，她曾在Shire，Inc.（Shire）担任多个关键领导职位，包括眼科并购主管，并在扩大其眼科管道方面发挥了重要作用。作为Shire新产品的负责人，她领导了眼科创新委员会，该委员会塑造并执行了特许经营的增长战略。在加入Shire之前，Benton女士曾于2011年9月至2013年9月在Bausch + Lomb制药（B + L）担任全球业务发展领导职务，她和企业发展团队在三年内处理了十多笔交易。她是一家眼科初创公司Sirion Therapeutics，Inc.的联合创始人和首席商务官，她推出并监督了Durezol的商业化和Zirgan之前分别出售给了爱尔康和B + L。Benton女士于1995年3月在B + L开始了她的眼科职业生涯，在那里她担任了领导职务，担任多元化产品主管和专业销售副总裁。在她任职期间，她建立并配备了一支由75名销售专业人员组成的团队，并推出了B + L首个品牌产品Lotemax和Alrex，除了Optivar通过与Muro Pharmaceutical的共同推广。她还担任过十几家初创型眼科企业的战略顾问。她在眼科之外的经验包括担任强生糖尿病专营权LifeScan的消费者和专业销售副总裁，以及在赛诺菲巴斯德疫苗业务中担任高级经理职务。本顿女士获得了南佛罗里达大学的工商管理硕士学位和穆伦伯格学院的生物学学士学位。
- Susan K. Benton,serves as the President for Thea Pharma, Inc. (Thea), a wholly-owned subsidiary of Thea Laboratories, a leading independent ophthalmic pharmaceutical company, a position she has held since August 2019. Ms. Benton also serves on the boards of two privately held ophthalmic companies: Tarsius Pharma Ltd. (since March 2019) and Ripple Therapeutics (since March 2022). From April 2015 through July 2019, she served in a number of key leadership positions at Shire, Inc. (Shire), including Head of M&A for Ophthalmology, and played an instrumental role in the expansion of its ophthalmic pipeline. As the Head of New Products at Shire, she led the Ophthalmic Innovation Committee that shaped and executed the growth strategy for the franchise. Before joining Shire, Ms. Benton served in a leadership capacity in Global Business Development for Bausch + Lomb Pharmaceuticals (B+L) from September 2011 through September 2013, where she and the Corporate Development team transacted over ten deals in three years. She was a co-Founder and Chief Commercial Officer for an ophthalmic start-up, Sirion Therapeutics, Inc., and she launched and oversaw the commercialization of Durezol and Zirgan before they were sold to Alcon and B+L, respectively. Ms. Benton began her ophthalmic career at B+L in March 1995, where she assumed leadership roles as the Head of Diversified Products and the VP of Professional Sales. During her tenure, she built and staffed a team of 75 sales professionals and she launched B+L's first ever branded products, Lotemax and Alrex, in addition to Optivar through a co-promote with Muro Pharmaceutical. She has also served as a strategic consultant for more than a dozen start-up ophthalmic companies. Her experience outside of ophthalmology includes roles as the VP of Consumer and Professional Sales for Johnson & Johnson's diabetes franchise, LifeScan, and senior manager roles in Sanofi Pasteur's vaccine business. Ms. Benton earned her M.B.A from the University of South Florida and a B.S. in Biology from Muhlenberg College.
- Benjamin R. Yerxa
-
Benjamin R. Yerxa也已被任命为Ocuphire的总裁，自2024年10月22日起生效。Yerxa博士自2022年7月起担任Opus的首席执行官兼总裁。Yerxa博士此前曾于2017年10月开始担任抗击失明基金会（“FFB”）的首席执行官，该基金会推动研究，为患有视网膜退行性疾病的人提供治疗和治愈，他在那里成立了视网膜退化基金，这是一家风险慈善投资基金。在加入FFB之前，Yerxa博士曾担任Envisia Therapeutics，Inc.的总裁和联合创始人，该公司专注于为眼睛的前部和后部开发新型眼部持续递送疗法。他此前还曾在多家以眼科为基础的研究机构担任创始人和高管职务，包括专注于肺动脉高压产品开发和商业化的生物制药公司Liquidia Technologies, Inc.、专注于通过脉络膜上间隙向眼后部提供疗法的生物制药公司Clearside生物医学公司（“Clearside”）、开发治疗呼吸道疾病先天性粘膜防御系统缺陷的疗法的公司Parion Sciences，Inc.，以及专注于开发和商业化眼科眼科产品的专业制药公司激励制药。Yerxa博士还自2022年3月起担任Clearside和Nacuity Pharmaceuticals，Inc.的董事会成员，Nacuity Pharmaceuticals，Inc.是自2019年10月以来氧化应激创新疗法的临床阶段领导者。Yerxa博士拥有60项美国专利。Yerxa博士在加州大学欧文分校获得有机化学博士学位，在加州大学圣地亚哥分校获得化学学士学位。
Benjamin R. Yerxa,has also been appointed to serve as Ocuphire's President, effective October 22, 2024. Dr. Yerxa has been the Chief Executive Officer and President of Opus since July 2022. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness ("FFB") starting in October 2017, a foundation that drives research to provide treatments and cures for people afflicted by retinal degenerative diseases, where he established the Retinal Degeneration Fund, a venture philanthropy investment fund. Prior to joining FFB, Dr. Yerxa served as President and Co-Founder of Envisia Therapeutics, Inc., a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. He also has previously held founding and executive positions in several ophthalmology-based research organizations, including Liquidia Technologies, Inc., a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension, Clearside Biomedical, Inc. ("Clearside"), a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space, Parion Sciences, Inc., a company that develops therapies to treat defects of the innate mucosal defense system in respiratory diseases, and Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Dr. Yerxa has also served on the boards of directors of Clearside since March 2022 and Nacuity Pharmaceuticals, Inc., a clinical-stage leader in innovative treatments for oxidative stress since October 2019. Dr. Yerxa holds 60 U.S. patents. Dr. Yerxa earned his Ph.D. in organic chemistry from the University of California, Irvine, and his B.A. in chemistry from the University of California, San Diego. - Benjamin R. Yerxa也已被任命为Ocuphire的总裁，自2024年10月22日起生效。Yerxa博士自2022年7月起担任Opus的首席执行官兼总裁。Yerxa博士此前曾于2017年10月开始担任抗击失明基金会（“FFB”）的首席执行官，该基金会推动研究，为患有视网膜退行性疾病的人提供治疗和治愈，他在那里成立了视网膜退化基金，这是一家风险慈善投资基金。在加入FFB之前，Yerxa博士曾担任Envisia Therapeutics，Inc.的总裁和联合创始人，该公司专注于为眼睛的前部和后部开发新型眼部持续递送疗法。他此前还曾在多家以眼科为基础的研究机构担任创始人和高管职务，包括专注于肺动脉高压产品开发和商业化的生物制药公司Liquidia Technologies, Inc.、专注于通过脉络膜上间隙向眼后部提供疗法的生物制药公司Clearside生物医学公司（“Clearside”）、开发治疗呼吸道疾病先天性粘膜防御系统缺陷的疗法的公司Parion Sciences，Inc.，以及专注于开发和商业化眼科眼科产品的专业制药公司激励制药。Yerxa博士还自2022年3月起担任Clearside和Nacuity Pharmaceuticals，Inc.的董事会成员，Nacuity Pharmaceuticals，Inc.是自2019年10月以来氧化应激创新疗法的临床阶段领导者。Yerxa博士拥有60项美国专利。Yerxa博士在加州大学欧文分校获得有机化学博士学位，在加州大学圣地亚哥分校获得化学学士学位。
- Benjamin R. Yerxa,has also been appointed to serve as Ocuphire's President, effective October 22, 2024. Dr. Yerxa has been the Chief Executive Officer and President of Opus since July 2022. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness ("FFB") starting in October 2017, a foundation that drives research to provide treatments and cures for people afflicted by retinal degenerative diseases, where he established the Retinal Degeneration Fund, a venture philanthropy investment fund. Prior to joining FFB, Dr. Yerxa served as President and Co-Founder of Envisia Therapeutics, Inc., a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. He also has previously held founding and executive positions in several ophthalmology-based research organizations, including Liquidia Technologies, Inc., a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension, Clearside Biomedical, Inc. ("Clearside"), a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space, Parion Sciences, Inc., a company that develops therapies to treat defects of the innate mucosal defense system in respiratory diseases, and Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Dr. Yerxa has also served on the boards of directors of Clearside since March 2022 and Nacuity Pharmaceuticals, Inc., a clinical-stage leader in innovative treatments for oxidative stress since October 2019. Dr. Yerxa holds 60 U.S. patents. Dr. Yerxa earned his Ph.D. in organic chemistry from the University of California, Irvine, and his B.A. in chemistry from the University of California, San Diego.
- Jean Bennett
-
Jean Bennett 2024 –至今：宾夕法尼亚大学佩雷尔曼医学院F.M. 卡比海运眼科名誉教授；2017 – 2020年：Limelight Bio Inc.联合创始人，一家私营基因治疗公司；2014 –至今：宾夕法尼亚大学高级视网膜和眼部治疗中心主任；2013 –至今：前上市基因治疗公司星火治疗公司联合创始人；2012 – 2024年：上市眼部基因治疗公司GenSight Biologics S.A.（EPA：SIGHT）联合创始人；2005 –至今：费城儿童医院细胞和分子治疗中心研究员。加州大学动物学和细胞生物学博士，伯克利，哈佛大学医学院医学博士，耶鲁大学生物学学士，加州大学旧金山分校放射生物学和环境健康研究金，耶鲁大学医学院人类遗传学研究金，约翰霍普金斯大学医学院发展遗传学研究金。
Jean Bennett 2024 – Present:F.M. Kirby Emerit Professor of Ophthalmology, Perelman School of Medicine of the University of Pennsylvania;2017 – 2020:Co founder, Limelight Bio Inc., a private gene therapy company;2014 – Present:Director, Center for Advanced Retinal and Ocular Therapeutics at the University of Pennsylvania;2013 – Present:Co founder, Spark Therapeutics, Inc., a formerly public gene therapy company;2012 – 2024:Co founder, GenSight Biologics S.A. (EPA: SIGHT), a public ocular gene therapy company;2005 – Present:Investigator, Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia.Ph.D. in Zoology and Cell Biology from the University of California, Berkeley,M.D. from Harvard University Medical School,B.S. in Biology from Yale University,Fellowship in Radiobiology and Environmental Health at the University of California, San Francisco,Fellowship in Human Genetics at Yale School of Medicine,Fellowship in Development Genetics at the Johns Hopkins University School of Medicine. - Jean Bennett 2024 –至今：宾夕法尼亚大学佩雷尔曼医学院F.M. 卡比海运眼科名誉教授；2017 – 2020年：Limelight Bio Inc.联合创始人，一家私营基因治疗公司；2014 –至今：宾夕法尼亚大学高级视网膜和眼部治疗中心主任；2013 –至今：前上市基因治疗公司星火治疗公司联合创始人；2012 – 2024年：上市眼部基因治疗公司GenSight Biologics S.A.（EPA：SIGHT）联合创始人；2005 –至今：费城儿童医院细胞和分子治疗中心研究员。加州大学动物学和细胞生物学博士，伯克利，哈佛大学医学院医学博士，耶鲁大学生物学学士，加州大学旧金山分校放射生物学和环境健康研究金，耶鲁大学医学院人类遗传学研究金，约翰霍普金斯大学医学院发展遗传学研究金。
- Jean Bennett 2024 – Present:F.M. Kirby Emerit Professor of Ophthalmology, Perelman School of Medicine of the University of Pennsylvania;2017 – 2020:Co founder, Limelight Bio Inc., a private gene therapy company;2014 – Present:Director, Center for Advanced Retinal and Ocular Therapeutics at the University of Pennsylvania;2013 – Present:Co founder, Spark Therapeutics, Inc., a formerly public gene therapy company;2012 – 2024:Co founder, GenSight Biologics S.A. (EPA: SIGHT), a public ocular gene therapy company;2005 – Present:Investigator, Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia.Ph.D. in Zoology and Cell Biology from the University of California, Berkeley,M.D. from Harvard University Medical School,B.S. in Biology from Yale University,Fellowship in Radiobiology and Environmental Health at the University of California, San Francisco,Fellowship in Human Genetics at Yale School of Medicine,Fellowship in Development Genetics at the Johns Hopkins University School of Medicine.
- Adrienne Graves
-
Adrienne Graves 2010 –至今：青光眼360的共同创始人，青光眼研究基金会的年度项目，一家私营眼科非营利组织；2002 – 2010年：上市眼科制药公司参天制药股份有限公司（TSE：4536）总裁兼首席执行官，1995 – 2002年：参天制药有限公司全球临床开发高级副总裁1986 – 1995年：眼科医疗公司丨爱尔康爱尔康 Laboratories，Inc.（在纽约证券交易所上市前）国际眼科总监。密歇根大学心理生物学/神经科学博士，布朗大学心理学荣誉学士，巴黎大学视觉神经科学博士后奖学金。
Adrienne Graves 2010 – Present:Co founder, Glaucoma 360, an annual program for the Glaucoma Research Foundation, a private ophthalmic nonprofit organization;2002 – 2010:President and Chief Executive Officer, Santen Pharmaceutical Co., Ltd. (TSE: 4536), a public ophthalmic pharmaceutical company,1995 – 2002:Senior Vice President of Worldwide Clinical Development, Santen Pharmaceutical Co., Ltd.1986 – 1995:Director of International Ophthalmology, Alcon Laboratories, Inc. (prior to its listing on NYSE), an ophthalmic medical company.Ph.D. in Psychobiology/Neuroscience from the University of Michigan,B.A. with Honors in Psychology from Brown University,Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. - Adrienne Graves 2010 –至今：青光眼360的共同创始人，青光眼研究基金会的年度项目，一家私营眼科非营利组织；2002 – 2010年：上市眼科制药公司参天制药股份有限公司（TSE：4536）总裁兼首席执行官，1995 – 2002年：参天制药有限公司全球临床开发高级副总裁1986 – 1995年：眼科医疗公司丨爱尔康爱尔康 Laboratories，Inc.（在纽约证券交易所上市前）国际眼科总监。密歇根大学心理生物学/神经科学博士，布朗大学心理学荣誉学士，巴黎大学视觉神经科学博士后奖学金。
- Adrienne Graves 2010 – Present:Co founder, Glaucoma 360, an annual program for the Glaucoma Research Foundation, a private ophthalmic nonprofit organization;2002 – 2010:President and Chief Executive Officer, Santen Pharmaceutical Co., Ltd. (TSE: 4536), a public ophthalmic pharmaceutical company,1995 – 2002:Senior Vice President of Worldwide Clinical Development, Santen Pharmaceutical Co., Ltd.1986 – 1995:Director of International Ophthalmology, Alcon Laboratories, Inc. (prior to its listing on NYSE), an ophthalmic medical company.Ph.D. in Psychobiology/Neuroscience from the University of Michigan,B.A. with Honors in Psychology from Brown University,Postdoctoral Fellowship in Visual Neuroscience at the University of Paris.
- James S. Manuso
-
James S. Manuso，曾担任Astex Pharmaceuticals， Inc.（一家商业阶段的国际公司）的董事长兼首席执行官，之后领导将Astex出售给Otsuka Pharmaceuticals。在Astex任职期间，他负责监督多项国内和国际收购。2013年，他担任Otsuka Pharmaceuticals执行管理层的高级并购顾问。2015年以来，他担任Talfinium Investments， Inc.（投资实体和财务咨询公司）的董事长兼首席执行官。从2015年到2018年，他担任呼吸器制药公司（一家三期准备，临床阶段呼吸和神经制药公司）的总裁，首席执行官和副董事长。自2018年以来，他一直担任Laurelside LLC（他创立的家族办公室）的管理成员。他曾担任多家上市公司的董事会成员，包括Novelos Therapeutics， Inc.（现为Cellectar Biosciences（纳斯达克股票代码：CLRB））， Merrion Pharmaceuticals Ltd., Inflazyme Pharmaceuticals, Inc.和symbionics， Inc.（出售给BioMarin Pharmaceutical Inc.（纳斯达克股票代码：BMRN））。他还担任Quark Pharmaceuticals， Inc.和Montigen Pharmaceuticals， Inc.（他共同创立的公司）的董事会成员，Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc.和EuroGen， Ltd.（伦敦，英国）的董事会成员，并担任主席。他也是BIO （Biotechnology Innovation Organization）和the Greater San Francisco Bay Area Leukemia & Lymphoma Society的董事会成员，在那里他还担任副总裁。他曾担任H.C. Wainwright & Co.的副主席兼并购主管。他目前担任TuHura Biosciences， Inc.（一家私营免疫治疗开发商，反向合并到Kintara（纳斯达克股票代码：KTRA））的董事会成员。他持有New School大学的实验心理学和遗传学博士学位，以及Columbia Business School的执行工商管理硕士学位。他是一项药物专利和30多篇文章、章节和书籍的作者。他曾任职于哥伦比亚大学和纽约大学商学院的兼职教员。
James S. Manuso,served as Chairman and Chief Executive Officer of Astex Pharmaceuticals, Inc. (Astex), a commercial-stage, international company, before leading the sale of Astex to Otsuka Pharmaceuticals. While at Astex, Dr. Manuso oversaw multiple domestic and international acquisitions. In 2013, he was a Senior Mergers and Acquisitions Advisor to Otsuka Pharmaceuticals executive management. Since 2015, Dr. Manuso has served as chairman and Chief Executive Officer of Talfinium Investments, Inc., an investment entity and financial consultancy. From 2015 until 2018, Dr. Manuso served as President, Chief Executive Officer and Vice Chairman of RespireRx Pharmaceuticals Inc., a Phase 3-ready, clinical-stage respiratory and neurological pharmaceutical company. Since 2018, Dr. Manuso has served as Managing Member of Laurelside LLC, a family office, which he founded. Dr. Manuso has served on the boards of multiple public companies, including, Novelos Therapeutics, Inc. (now Cellectar Biosciences (Nasdaq: CLRB)), Merrion Pharmaceuticals Ltd., Inflazyme Pharmaceuticals, Inc., and Symbiontics, Inc., (sold to BioMarin Pharmaceutical Inc. (Nasdaq: BMRN)). He also served on the boards Quark Pharmaceuticals, Inc. and Montigen Pharmaceuticals, Inc., which he co-founded, Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK), where he served as Chairman. Dr. Manuso was also on the boards of BIO (Biotechnology Innovation Organization) and the Greater San Francisco Bay Area Leukemia & Lymphoma Society, where he also served as Vice President. Dr. Manuso previously served as Vice Chair and Head of M&A at H.C. Wainwright & Co. He currently serves on the board of directors of TuHura Biosciences, Inc., a private immunotherapeutic developer that is reverse-merging into Kintara (Nasdaq: KTRA). Dr. Manuso holds a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychology and Genetics from the New School University, and an Executive M.B.A. from Columbia Business School. Dr. Manuso is the author of a pharmaceutical patent and over 30 articles, chapters, and books. He has served on the adjunct faculties of the business schools of Columbia University and New York University. - James S. Manuso，曾担任Astex Pharmaceuticals， Inc.（一家商业阶段的国际公司）的董事长兼首席执行官，之后领导将Astex出售给Otsuka Pharmaceuticals。在Astex任职期间，他负责监督多项国内和国际收购。2013年，他担任Otsuka Pharmaceuticals执行管理层的高级并购顾问。2015年以来，他担任Talfinium Investments， Inc.（投资实体和财务咨询公司）的董事长兼首席执行官。从2015年到2018年，他担任呼吸器制药公司（一家三期准备，临床阶段呼吸和神经制药公司）的总裁，首席执行官和副董事长。自2018年以来，他一直担任Laurelside LLC（他创立的家族办公室）的管理成员。他曾担任多家上市公司的董事会成员，包括Novelos Therapeutics， Inc.（现为Cellectar Biosciences（纳斯达克股票代码：CLRB））， Merrion Pharmaceuticals Ltd., Inflazyme Pharmaceuticals, Inc.和symbionics， Inc.（出售给BioMarin Pharmaceutical Inc.（纳斯达克股票代码：BMRN））。他还担任Quark Pharmaceuticals， Inc.和Montigen Pharmaceuticals， Inc.（他共同创立的公司）的董事会成员，Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc.和EuroGen， Ltd.（伦敦，英国）的董事会成员，并担任主席。他也是BIO （Biotechnology Innovation Organization）和the Greater San Francisco Bay Area Leukemia & Lymphoma Society的董事会成员，在那里他还担任副总裁。他曾担任H.C. Wainwright & Co.的副主席兼并购主管。他目前担任TuHura Biosciences， Inc.（一家私营免疫治疗开发商，反向合并到Kintara（纳斯达克股票代码：KTRA））的董事会成员。他持有New School大学的实验心理学和遗传学博士学位，以及Columbia Business School的执行工商管理硕士学位。他是一项药物专利和30多篇文章、章节和书籍的作者。他曾任职于哥伦比亚大学和纽约大学商学院的兼职教员。
- James S. Manuso,served as Chairman and Chief Executive Officer of Astex Pharmaceuticals, Inc. (Astex), a commercial-stage, international company, before leading the sale of Astex to Otsuka Pharmaceuticals. While at Astex, Dr. Manuso oversaw multiple domestic and international acquisitions. In 2013, he was a Senior Mergers and Acquisitions Advisor to Otsuka Pharmaceuticals executive management. Since 2015, Dr. Manuso has served as chairman and Chief Executive Officer of Talfinium Investments, Inc., an investment entity and financial consultancy. From 2015 until 2018, Dr. Manuso served as President, Chief Executive Officer and Vice Chairman of RespireRx Pharmaceuticals Inc., a Phase 3-ready, clinical-stage respiratory and neurological pharmaceutical company. Since 2018, Dr. Manuso has served as Managing Member of Laurelside LLC, a family office, which he founded. Dr. Manuso has served on the boards of multiple public companies, including, Novelos Therapeutics, Inc. (now Cellectar Biosciences (Nasdaq: CLRB)), Merrion Pharmaceuticals Ltd., Inflazyme Pharmaceuticals, Inc., and Symbiontics, Inc., (sold to BioMarin Pharmaceutical Inc. (Nasdaq: BMRN)). He also served on the boards Quark Pharmaceuticals, Inc. and Montigen Pharmaceuticals, Inc., which he co-founded, Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK), where he served as Chairman. Dr. Manuso was also on the boards of BIO (Biotechnology Innovation Organization) and the Greater San Francisco Bay Area Leukemia & Lymphoma Society, where he also served as Vice President. Dr. Manuso previously served as Vice Chair and Head of M&A at H.C. Wainwright & Co. He currently serves on the board of directors of TuHura Biosciences, Inc., a private immunotherapeutic developer that is reverse-merging into Kintara (Nasdaq: KTRA). Dr. Manuso holds a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychology and Genetics from the New School University, and an Executive M.B.A. from Columbia Business School. Dr. Manuso is the author of a pharmaceutical patent and over 30 articles, chapters, and books. He has served on the adjunct faculties of the business schools of Columbia University and New York University.
- Richard Rodgers
-
Richard Rodgers自2014年12月起担任董事。除了在Rexahn的董事会席位外，罗杰斯先生目前还在Ardelyx，Inc.和3-V Biosciences，Inc.的董事会任职。罗杰斯先生此前曾在2010年3月至2013年8月期间担任他与人共同创立的专注于肿瘤学的生物制药公司TESARO的执行副总裁、首席财务官、秘书和财务主管。曾于2009年6月至2010年2月在Abraxis BioScience担任首席财务官，该公司随后被Celgene收购。在此之前，Rodgers先生曾在2004年至2008年1月被卫材收购之前担任MGI制药公司的高级副总裁、财务总监兼首席会计官。他曾在多家私营和上市公司担任财务和会计职务，包括Arthur Anderson。Rodgers先生获得了圣克劳德州立大学的财务会计学士学位和明尼苏达大学卡尔森商学院的金融MBA学位。
Richard Rodgers has served as a director since December 2014. In addition to his board seat with Rexahn, Mr. Rodgers currently serves on the Board of Directors of Ardelyx, Inc. and 3-V Biosciences, Inc. Mr. Rodgers was previously Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, an oncology-focused biopharmaceutical company that he co-founded, from March 2010 until August 2013. He served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience, which was subsequently acquired by Celgene. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, from 2004 until its acquisition by Eisai in January 2008. He has held finance and accounting positions at several private and public companies, including Arthur Anderson. Mr. Rodgers received a B.S. in Financial Accounting from St. Cloud State University and his MBA in Finance from the University of Minnesota, Carlson School of Business. - Richard Rodgers自2014年12月起担任董事。除了在Rexahn的董事会席位外，罗杰斯先生目前还在Ardelyx，Inc.和3-V Biosciences，Inc.的董事会任职。罗杰斯先生此前曾在2010年3月至2013年8月期间担任他与人共同创立的专注于肿瘤学的生物制药公司TESARO的执行副总裁、首席财务官、秘书和财务主管。曾于2009年6月至2010年2月在Abraxis BioScience担任首席财务官，该公司随后被Celgene收购。在此之前，Rodgers先生曾在2004年至2008年1月被卫材收购之前担任MGI制药公司的高级副总裁、财务总监兼首席会计官。他曾在多家私营和上市公司担任财务和会计职务，包括Arthur Anderson。Rodgers先生获得了圣克劳德州立大学的财务会计学士学位和明尼苏达大学卡尔森商学院的金融MBA学位。
- Richard Rodgers has served as a director since December 2014. In addition to his board seat with Rexahn, Mr. Rodgers currently serves on the Board of Directors of Ardelyx, Inc. and 3-V Biosciences, Inc. Mr. Rodgers was previously Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, an oncology-focused biopharmaceutical company that he co-founded, from March 2010 until August 2013. He served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience, which was subsequently acquired by Celgene. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, from 2004 until its acquisition by Eisai in January 2008. He has held finance and accounting positions at several private and public companies, including Arthur Anderson. Mr. Rodgers received a B.S. in Financial Accounting from St. Cloud State University and his MBA in Finance from the University of Minnesota, Carlson School of Business.
- Cam Gallagher
-
Cam Gallagher，他拥有工商管理硕士学位。他一直担任公司的董事（自2012年9月以来）。他目前担任Nerveda公司（他于2009年6月创立的生命科学种子基金）的唯一董事总经理。此前，从2007年9月到2009年6月，他曾担任Nerveda公司（私人持有的专业制药公司，位于加利福尼亚圣迭戈）的总裁兼首席执行官。2008年10月以来，他曾一直担任DioGenix公司（位于马里兰州盖瑟斯堡的一家私人持有的分子诊断公司）的董事会主席。他目前担任Neurelis公司（私人持有的专业制药公司，位于加利福尼亚圣迭戈）的负责业务拓展高级副总裁。从2004年12月到2007年6月，他曾担任Verus Pharmaceuticals公司（私人持有的专业制药公司，位于加利福尼亚圣迭戈）的多种职务，并不断被提拔。他获得the University of San Diego的工商管理硕士学位，以及俄亥俄州立大学（Ohio University）的工商管理学士学位。
Cam Gallagher,has served as a director since September 2012. Mr. Gallagher currently serves as the sole Managing Director of Nerveda, LLC, a life science seed fund he founded in June 2009. Previously, from September 2007 until June 2009 Mr. Gallagher served as President and Chief Executive Officer of Nerveda, Inc., a privately held specialty pharmaceutical company in San Diego, California. Since October 2008 Mr. Gallagher has served as Chairman of the Board of Directors of DioGenix, a privately held molecular diagnostic company in Gaithersburg, Maryland. Mr. Gallagher is currently acting as the Senior Vice President of Business Development for Neurelis, a privately held specialty pharmaceutical company in San Diego, California. From December 2004 through June 2007 Mr. Gallagher served in various senior marketing positions of increasing responsibility at Verus Pharmaceuticals, a privately held specialty pharmaceutical company in San Diego, California. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.S. in Business Administration from the Ohio University. - Cam Gallagher，他拥有工商管理硕士学位。他一直担任公司的董事（自2012年9月以来）。他目前担任Nerveda公司（他于2009年6月创立的生命科学种子基金）的唯一董事总经理。此前，从2007年9月到2009年6月，他曾担任Nerveda公司（私人持有的专业制药公司，位于加利福尼亚圣迭戈）的总裁兼首席执行官。2008年10月以来，他曾一直担任DioGenix公司（位于马里兰州盖瑟斯堡的一家私人持有的分子诊断公司）的董事会主席。他目前担任Neurelis公司（私人持有的专业制药公司，位于加利福尼亚圣迭戈）的负责业务拓展高级副总裁。从2004年12月到2007年6月，他曾担任Verus Pharmaceuticals公司（私人持有的专业制药公司，位于加利福尼亚圣迭戈）的多种职务，并不断被提拔。他获得the University of San Diego的工商管理硕士学位，以及俄亥俄州立大学（Ohio University）的工商管理学士学位。
- Cam Gallagher,has served as a director since September 2012. Mr. Gallagher currently serves as the sole Managing Director of Nerveda, LLC, a life science seed fund he founded in June 2009. Previously, from September 2007 until June 2009 Mr. Gallagher served as President and Chief Executive Officer of Nerveda, Inc., a privately held specialty pharmaceutical company in San Diego, California. Since October 2008 Mr. Gallagher has served as Chairman of the Board of Directors of DioGenix, a privately held molecular diagnostic company in Gaithersburg, Maryland. Mr. Gallagher is currently acting as the Senior Vice President of Business Development for Neurelis, a privately held specialty pharmaceutical company in San Diego, California. From December 2004 through June 2007 Mr. Gallagher served in various senior marketing positions of increasing responsibility at Verus Pharmaceuticals, a privately held specialty pharmaceutical company in San Diego, California. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.S. in Business Administration from the Ohio University.
高管简历
中英对照 | 中文 | 英文- Robert Gagnon
Robert Gagnon目前在Opus Genetics担任首席财务官，他于2025年8月开始担任这一职务。在此之前，他于2023年3月至2025年8月担任Remix Therapeutics的首席财务官，于2022年10月至2023年6月担任医疗健康风险投资和私募股权基金Gurnet Point Capital的运营合伙人，于2018年8月至2022年10月担任Verastem，于2013年11月至2018年8月担任哈佛生物科学，于2012年至2013年担任清洁海港，Inc.的运营合伙人。他的职业经历还包括在渤健 Idec、德勤会计师事务所和普华永道担任高级职务。加格农先生在麻省理工学院斯隆获得工商管理硕士学位，在本特利学院获得会计学士学位。
Robert Gagnon is currently the Chief Financial Officer at Opus Genetics, a role he started in August 2025. Prior to that, he served as CFO for Remix Therapeutics from March 2023 to August 2025, as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund, from October 2022 to June 2023, Verastem, Inc. from August 2018 to October 2022, Harvard Bioscience, Inc. from November 2013 to August 2018, and Clean Harbors, Inc. between 2012 and 2013. His professional experience also includes senior roles at Biogen Idec, Deloitte & Touche, and PricewaterhouseCoopers. Mr. Gagnon earned his M.B.A. from MIT Sloan and a B.A. in accounting from Bentley College.- Robert Gagnon目前在Opus Genetics担任首席财务官，他于2025年8月开始担任这一职务。在此之前，他于2023年3月至2025年8月担任Remix Therapeutics的首席财务官，于2022年10月至2023年6月担任医疗健康风险投资和私募股权基金Gurnet Point Capital的运营合伙人，于2018年8月至2022年10月担任Verastem，于2013年11月至2018年8月担任哈佛生物科学，于2012年至2013年担任清洁海港，Inc.的运营合伙人。他的职业经历还包括在渤健 Idec、德勤会计师事务所和普华永道担任高级职务。加格农先生在麻省理工学院斯隆获得工商管理硕士学位，在本特利学院获得会计学士学位。
- Robert Gagnon is currently the Chief Financial Officer at Opus Genetics, a role he started in August 2025. Prior to that, he served as CFO for Remix Therapeutics from March 2023 to August 2025, as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund, from October 2022 to June 2023, Verastem, Inc. from August 2018 to October 2022, Harvard Bioscience, Inc. from November 2013 to August 2018, and Clean Harbors, Inc. between 2012 and 2013. His professional experience also includes senior roles at Biogen Idec, Deloitte & Touche, and PricewaterhouseCoopers. Mr. Gagnon earned his M.B.A. from MIT Sloan and a B.A. in accounting from Bentley College.
- George Magrath
George Magrath，自2023年11月担任Opus Genetics，Inc.首席执行官。Magrath博士此前担任Lexitas Pharmaceutical Services，Inc.（Lexitas）的首席执行官，他在2021年2月至2023年9月期间担任该职位，领导该公司从35名员工增长到超过200名员工，并监督公司的出售。随后，Magrath博士在2023年9月至2023年10月期间担任Lexitas的顾问。在担任这些职务之前，他曾于2020年8月至2021年1月在Lexitas担任首席医疗官。Magrath博士此前还曾于2015年8月至2020年8月担任Hovione Pharmaceuticals，LLC的医疗总监。Magrath博士于2021年8月至2023年9月担任Lexitas的董事会成员，并于2022年3月至2023年10月担任Line 6 Biotechnology，Inc.的科学顾问委员会成员，并于2019年11月至2023年1月担任ONO Pharmaceutical Co.，Ltd.的科学顾问委员会成员。他是Implicit Bioscience的董事会观察员（自2022年起）和Foundation Fighting Blindness Translational Research Acceleration Program的顾问委员会成员（自2022年起）。Magrath博士已完成卡内基梅隆大学和美国国家公司董事协会网络安全监督学CERT证书的要求。Magrath博士获得了Citadel的工商管理硕士学位、南卡罗来纳医科大学的医学博士学位、约翰霍普金斯大学的应用经济学硕士学位和克莱姆森大学的生物化学学士学位。Magrath博士还是两项授权专利的共同发明人，撰写了超过25篇同行评审文章。Magrath博士还曾于2016年至2017年在Edison Investment Research担任股票分析师。
George Magrath,has served as Opus Genetics, Inc. Chief Executive Officer since November 2023. Dr. Magrath was previously Chief Executive Officer of Lexitas Pharmaceutical Services, Inc. (Lexitas), a position he served in from February 2021 through September 2023, leading the company's growth from 35 to over 200 employees and overseeing the sale of the company. Dr. Magrath then served as a consultant to Lexitas from September 2023 through October 2023. Prior to serving in these roles, he served with Lexitas as its Chief Medical Officer from August 2020 to January 2021. Dr. Magrath has also previously served as medical director at Hovione Pharmaceuticals, LLC from August 2015 to August 2020. Dr. Magrath served on the board of directors of Lexitas from August 2021 through September 2023 and as a scientific advisory board member of Line 6 Biotechnology, Inc. from March 2022 to October 2023 and ONO Pharmaceutical Co., Ltd. from November 2019 to January 2023. He is a board observer of Implicit Bioscience (since 2022) and on the advisory board of Foundation Fighting Blindness Translational Research Acceleration Program (since 2022). Dr. Magrath has completed the requirements for the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University and the National Association of Corporate Directors. Dr. Magrath earned his M.B.A. from The Citadel, his M.D. from Medical University of South Carolina, his M.S. in Applied Economics from Johns Hopkins University and his B.S. in Biological Chemistry from Clemson University. Dr. Magrath is also a co-inventor on two granted patents and has authored over 25 peer-reviewed articles. Dr. Magrath also worked as an equity analyst at Edison Investment Research from 2016 to 2017.- George Magrath，自2023年11月担任Opus Genetics，Inc.首席执行官。Magrath博士此前担任Lexitas Pharmaceutical Services，Inc.（Lexitas）的首席执行官，他在2021年2月至2023年9月期间担任该职位，领导该公司从35名员工增长到超过200名员工，并监督公司的出售。随后，Magrath博士在2023年9月至2023年10月期间担任Lexitas的顾问。在担任这些职务之前，他曾于2020年8月至2021年1月在Lexitas担任首席医疗官。Magrath博士此前还曾于2015年8月至2020年8月担任Hovione Pharmaceuticals，LLC的医疗总监。Magrath博士于2021年8月至2023年9月担任Lexitas的董事会成员，并于2022年3月至2023年10月担任Line 6 Biotechnology，Inc.的科学顾问委员会成员，并于2019年11月至2023年1月担任ONO Pharmaceutical Co.，Ltd.的科学顾问委员会成员。他是Implicit Bioscience的董事会观察员（自2022年起）和Foundation Fighting Blindness Translational Research Acceleration Program的顾问委员会成员（自2022年起）。Magrath博士已完成卡内基梅隆大学和美国国家公司董事协会网络安全监督学CERT证书的要求。Magrath博士获得了Citadel的工商管理硕士学位、南卡罗来纳医科大学的医学博士学位、约翰霍普金斯大学的应用经济学硕士学位和克莱姆森大学的生物化学学士学位。Magrath博士还是两项授权专利的共同发明人，撰写了超过25篇同行评审文章。Magrath博士还曾于2016年至2017年在Edison Investment Research担任股票分析师。
- George Magrath,has served as Opus Genetics, Inc. Chief Executive Officer since November 2023. Dr. Magrath was previously Chief Executive Officer of Lexitas Pharmaceutical Services, Inc. (Lexitas), a position he served in from February 2021 through September 2023, leading the company's growth from 35 to over 200 employees and overseeing the sale of the company. Dr. Magrath then served as a consultant to Lexitas from September 2023 through October 2023. Prior to serving in these roles, he served with Lexitas as its Chief Medical Officer from August 2020 to January 2021. Dr. Magrath has also previously served as medical director at Hovione Pharmaceuticals, LLC from August 2015 to August 2020. Dr. Magrath served on the board of directors of Lexitas from August 2021 through September 2023 and as a scientific advisory board member of Line 6 Biotechnology, Inc. from March 2022 to October 2023 and ONO Pharmaceutical Co., Ltd. from November 2019 to January 2023. He is a board observer of Implicit Bioscience (since 2022) and on the advisory board of Foundation Fighting Blindness Translational Research Acceleration Program (since 2022). Dr. Magrath has completed the requirements for the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University and the National Association of Corporate Directors. Dr. Magrath earned his M.B.A. from The Citadel, his M.D. from Medical University of South Carolina, his M.S. in Applied Economics from Johns Hopkins University and his B.S. in Biological Chemistry from Clemson University. Dr. Magrath is also a co-inventor on two granted patents and has authored over 25 peer-reviewed articles. Dr. Magrath also worked as an equity analyst at Edison Investment Research from 2016 to 2017.
- Joseph Schachle
Joseph Schachle，于2023年11月被任命为首席运营官。在加入公司之前，Schachle先生是Opus Genetics，Inc.的首席运营官，他在2021年10月至2023年3月期间担任该职位（在担任首席运营官之后，他在2023年4月至2023年12月期间担任Opus Genetics，Inc.的顾问）。在担任这些职务之前，他曾任职于全球医疗保健公司和血浆衍生药物领先制造商GRIFOLS, S.A.，于2017年8月至2020年2月担任全球商业服务与控制副总裁，并于2020年3月至2021年9月担任客户体验支持副总裁。Schachle先生在Old Dominion大学获得工商管理硕士学位，在James Madison大学获得市场营销领域的工商管理学士学位。
Joseph Schachle was Chief Operating Officer of Op's legacy company ("Legacy Op") from October 2021 through March 2023 (where, following his service as Chief Operating Officer, he served as a consultant to Legacy Op from April 2023 through December 2023). Prior to serving in these roles, he served with Grifols, S.A., a global healthcare company and leading manufacturer of plasma derived medicines, as its Vice President of Global Commercial Services & Controlling from Augt 2017 to February 2020 and its Vice President of Ctomer Experience Enablement from March 2020 to September 2021.- Joseph Schachle，于2023年11月被任命为首席运营官。在加入公司之前，Schachle先生是Opus Genetics，Inc.的首席运营官，他在2021年10月至2023年3月期间担任该职位（在担任首席运营官之后，他在2023年4月至2023年12月期间担任Opus Genetics，Inc.的顾问）。在担任这些职务之前，他曾任职于全球医疗保健公司和血浆衍生药物领先制造商GRIFOLS, S.A.，于2017年8月至2020年2月担任全球商业服务与控制副总裁，并于2020年3月至2021年9月担任客户体验支持副总裁。Schachle先生在Old Dominion大学获得工商管理硕士学位，在James Madison大学获得市场营销领域的工商管理学士学位。
- Joseph Schachle was Chief Operating Officer of Op's legacy company ("Legacy Op") from October 2021 through March 2023 (where, following his service as Chief Operating Officer, he served as a consultant to Legacy Op from April 2023 through December 2023). Prior to serving in these roles, he served with Grifols, S.A., a global healthcare company and leading manufacturer of plasma derived medicines, as its Vice President of Global Commercial Services & Controlling from Augt 2017 to February 2020 and its Vice President of Ctomer Experience Enablement from March 2020 to September 2021.
- Amy Rabourn
Amy Rabourn，于2023年1月晋升为财务高级副总裁。此前于2020年11月至2023年1月担任公司财务副总裁。Rabourn女士拥有超过20年的财务和会计经验，包括上市公司经验，专注于生命科学。在担任公司职务之前，她于2014年12月起担任Gemphire Therapeutics，Inc.（“Gemphire”）的财务总监，直至2019年12月该公司与NeuroBo制药公司（“NeuroBo”）合并。在Gemphire，Rabourn女士实施了通过私人筹资和2016年8月首次公开募股支持Gemphire的流程和程序。她负责监督日常财务交易，执行预算编制和预测，并管理财务审查和审计、SEC文件和税务准备。在Gemphire与NeuroBo合并后，她继续担任NeuroBo的顾问，担任该公司过渡到上市公司身份时的相同角色。在加入Gemphire之前，她曾担任一家软件初创公司的财务总监，在生命科学领域从事财务咨询工作，曾在辉瑞公司担任多个财务职位。她是一名有公共会计经验的持牌注册会计师，在普华永道会计师事务所开始了她的审计从业生涯。Rabourn女士拥有美国密歇根大学会计学硕士学位和金融和会计学学士学位。
Amy Rabourn previoly served as Senior Vice President of Finance from January 2023 through July 2025 and Vice President of Finance prior to that since November 2020. Ms. Rabn has over 20 years of finance and accounting experience, including public company experience, with a foc on life sciences. Prior to her roles with the Company, she served as Director of Finance at Gemphire Therapeutics, Inc. from December 2014 until its merger with NeuroBo Pharmaceuticals, Inc. in December 2019. At Gemphire, Ms. Rabn implemented processes and procedures that supported Gemphire through private fund raising and its initial public offering in August 2016. She oversaw daily financial transactions, performed budgeting and forecasting, and managed the financial reviews and audit, SEC filings and tax preparation. After Gemphire's merger with NeuroBo, she continued as a consultant to NeuroBo in the same role as it transitioned to public company stat. Prior to Gemphire, she held a position as Controller of a software start up, performed financial consulting in the life sciences space and worked in vario finance positions at Pfizer Inc. She is a licensed CPA with public accounting experience and began her career in the audit practice at PricewaterhoeCoopers, LLP. Ms. Rabn holds a Master of Accounting and B.B.A. Finance and Accounting concentration from the University of Michigan.- Amy Rabourn，于2023年1月晋升为财务高级副总裁。此前于2020年11月至2023年1月担任公司财务副总裁。Rabourn女士拥有超过20年的财务和会计经验，包括上市公司经验，专注于生命科学。在担任公司职务之前，她于2014年12月起担任Gemphire Therapeutics，Inc.（“Gemphire”）的财务总监，直至2019年12月该公司与NeuroBo制药公司（“NeuroBo”）合并。在Gemphire，Rabourn女士实施了通过私人筹资和2016年8月首次公开募股支持Gemphire的流程和程序。她负责监督日常财务交易，执行预算编制和预测，并管理财务审查和审计、SEC文件和税务准备。在Gemphire与NeuroBo合并后，她继续担任NeuroBo的顾问，担任该公司过渡到上市公司身份时的相同角色。在加入Gemphire之前，她曾担任一家软件初创公司的财务总监，在生命科学领域从事财务咨询工作，曾在辉瑞公司担任多个财务职位。她是一名有公共会计经验的持牌注册会计师，在普华永道会计师事务所开始了她的审计从业生涯。Rabourn女士拥有美国密歇根大学会计学硕士学位和金融和会计学学士学位。
- Amy Rabourn previoly served as Senior Vice President of Finance from January 2023 through July 2025 and Vice President of Finance prior to that since November 2020. Ms. Rabn has over 20 years of finance and accounting experience, including public company experience, with a foc on life sciences. Prior to her roles with the Company, she served as Director of Finance at Gemphire Therapeutics, Inc. from December 2014 until its merger with NeuroBo Pharmaceuticals, Inc. in December 2019. At Gemphire, Ms. Rabn implemented processes and procedures that supported Gemphire through private fund raising and its initial public offering in August 2016. She oversaw daily financial transactions, performed budgeting and forecasting, and managed the financial reviews and audit, SEC filings and tax preparation. After Gemphire's merger with NeuroBo, she continued as a consultant to NeuroBo in the same role as it transitioned to public company stat. Prior to Gemphire, she held a position as Controller of a software start up, performed financial consulting in the life sciences space and worked in vario finance positions at Pfizer Inc. She is a licensed CPA with public accounting experience and began her career in the audit practice at PricewaterhoeCoopers, LLP. Ms. Rabn holds a Master of Accounting and B.B.A. Finance and Accounting concentration from the University of Michigan.
- Benjamin R. Yerxa
Benjamin R. Yerxa也已被任命为Ocuphire的总裁，自2024年10月22日起生效。Yerxa博士自2022年7月起担任Opus的首席执行官兼总裁。Yerxa博士此前曾于2017年10月开始担任抗击失明基金会（“FFB”）的首席执行官，该基金会推动研究，为患有视网膜退行性疾病的人提供治疗和治愈，他在那里成立了视网膜退化基金，这是一家风险慈善投资基金。在加入FFB之前，Yerxa博士曾担任Envisia Therapeutics，Inc.的总裁和联合创始人，该公司专注于为眼睛的前部和后部开发新型眼部持续递送疗法。他此前还曾在多家以眼科为基础的研究机构担任创始人和高管职务，包括专注于肺动脉高压产品开发和商业化的生物制药公司Liquidia Technologies, Inc.、专注于通过脉络膜上间隙向眼后部提供疗法的生物制药公司Clearside生物医学公司（“Clearside”）、开发治疗呼吸道疾病先天性粘膜防御系统缺陷的疗法的公司Parion Sciences，Inc.，以及专注于开发和商业化眼科眼科产品的专业制药公司激励制药。Yerxa博士还自2022年3月起担任Clearside和Nacuity Pharmaceuticals，Inc.的董事会成员，Nacuity Pharmaceuticals，Inc.是自2019年10月以来氧化应激创新疗法的临床阶段领导者。Yerxa博士拥有60项美国专利。Yerxa博士在加州大学欧文分校获得有机化学博士学位，在加州大学圣地亚哥分校获得化学学士学位。
Benjamin R. Yerxa,has also been appointed to serve as Ocuphire's President, effective October 22, 2024. Dr. Yerxa has been the Chief Executive Officer and President of Opus since July 2022. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness ("FFB") starting in October 2017, a foundation that drives research to provide treatments and cures for people afflicted by retinal degenerative diseases, where he established the Retinal Degeneration Fund, a venture philanthropy investment fund. Prior to joining FFB, Dr. Yerxa served as President and Co-Founder of Envisia Therapeutics, Inc., a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. He also has previously held founding and executive positions in several ophthalmology-based research organizations, including Liquidia Technologies, Inc., a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension, Clearside Biomedical, Inc. ("Clearside"), a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space, Parion Sciences, Inc., a company that develops therapies to treat defects of the innate mucosal defense system in respiratory diseases, and Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Dr. Yerxa has also served on the boards of directors of Clearside since March 2022 and Nacuity Pharmaceuticals, Inc., a clinical-stage leader in innovative treatments for oxidative stress since October 2019. Dr. Yerxa holds 60 U.S. patents. Dr. Yerxa earned his Ph.D. in organic chemistry from the University of California, Irvine, and his B.A. in chemistry from the University of California, San Diego.- Benjamin R. Yerxa也已被任命为Ocuphire的总裁，自2024年10月22日起生效。Yerxa博士自2022年7月起担任Opus的首席执行官兼总裁。Yerxa博士此前曾于2017年10月开始担任抗击失明基金会（“FFB”）的首席执行官，该基金会推动研究，为患有视网膜退行性疾病的人提供治疗和治愈，他在那里成立了视网膜退化基金，这是一家风险慈善投资基金。在加入FFB之前，Yerxa博士曾担任Envisia Therapeutics，Inc.的总裁和联合创始人，该公司专注于为眼睛的前部和后部开发新型眼部持续递送疗法。他此前还曾在多家以眼科为基础的研究机构担任创始人和高管职务，包括专注于肺动脉高压产品开发和商业化的生物制药公司Liquidia Technologies, Inc.、专注于通过脉络膜上间隙向眼后部提供疗法的生物制药公司Clearside生物医学公司（“Clearside”）、开发治疗呼吸道疾病先天性粘膜防御系统缺陷的疗法的公司Parion Sciences，Inc.，以及专注于开发和商业化眼科眼科产品的专业制药公司激励制药。Yerxa博士还自2022年3月起担任Clearside和Nacuity Pharmaceuticals，Inc.的董事会成员，Nacuity Pharmaceuticals，Inc.是自2019年10月以来氧化应激创新疗法的临床阶段领导者。Yerxa博士拥有60项美国专利。Yerxa博士在加州大学欧文分校获得有机化学博士学位，在加州大学圣地亚哥分校获得化学学士学位。
- Benjamin R. Yerxa,has also been appointed to serve as Ocuphire's President, effective October 22, 2024. Dr. Yerxa has been the Chief Executive Officer and President of Opus since July 2022. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness ("FFB") starting in October 2017, a foundation that drives research to provide treatments and cures for people afflicted by retinal degenerative diseases, where he established the Retinal Degeneration Fund, a venture philanthropy investment fund. Prior to joining FFB, Dr. Yerxa served as President and Co-Founder of Envisia Therapeutics, Inc., a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. He also has previously held founding and executive positions in several ophthalmology-based research organizations, including Liquidia Technologies, Inc., a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension, Clearside Biomedical, Inc. ("Clearside"), a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space, Parion Sciences, Inc., a company that develops therapies to treat defects of the innate mucosal defense system in respiratory diseases, and Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Dr. Yerxa has also served on the boards of directors of Clearside since March 2022 and Nacuity Pharmaceuticals, Inc., a clinical-stage leader in innovative treatments for oxidative stress since October 2019. Dr. Yerxa holds 60 U.S. patents. Dr. Yerxa earned his Ph.D. in organic chemistry from the University of California, Irvine, and his B.A. in chemistry from the University of California, San Diego.
- Ashwath Jayagopal
Ashwath Jayagopal在2021年至2024年2月期间担任Legacy OP的首席科学官。2019年至2021年，他在Kodiak Sciences Inc.担任Discovery Medicine执行董事，负责监督早期投资组合开发，并于2015年至2019年在罗氏担任眼科分子药理学和生物标志物负责人。他在罗氏的成就包括领导开展发现和IND支持研究的团队，包括FDA批准的视网膜血管疾病治疗药物Vabysmo（基因泰克商标），眼科首个双特异性抗体。在从事工业职业之前，Jayagopal博士曾在范德比尔特大学医学中心范德比尔特眼科研究所担任助理教授和美国国立卫生研究院资助的首席研究员。Jayagopal博士是视力和眼科研究协会（ARVO）的研究员，也是眼科药理学和治疗协会（AOPT）的主席。他在基金会对抗失明创新咨询委员会和眼药理学和治疗学杂志Jnal的编辑委员会任职。Jayagopal博士拥有范德比尔特大学生物医学工程博士学位和印第安纳大学凯利比尼斯学院工商管理硕士学位。Jayagopal博士是40多篇同行审查出版物的作者，曾被授予罗氏关键贡献者奖、研究预防失明的多利·格林特别学者奖，以及美国糖尿病协会颁发的初级教员奖。
Ashwath Jayagopal served as the Chief Scientific Officer of Legacy Op from 2021 to February 2024. From 2019 to 2021, he served as Executive Director of Discovery Medicine at Kodiak Sciences Inc., where he supervised early stage portfolio development, and served as the Head of Molecular Pharmacology and Biomarkers in Ophthalmology at Roche from 2015 to 2019. His accomplishments at Roche included leadership of teams conducting discovery and IND enabling studies, including the FDA approved therapeutic for retinal vascular disease, Vabysmo (trademark of Genentech, Inc.), the first bispecific antibody in ophthalmology. Prior to his career in industry, Dr. Jayagopal served as an Assistant Professor and NIH funded Principal Investigator at the Vanderbilt Eye Institute, Vanderbilt University Medical Center. Dr. Jayagopal is a Fellow of the Association for Research in Vision and Ophthalmology (ARVO) as ll as a Fellow and the President of the Association for Ocular Pharmacology and Therapeutics (AOPT). He serves on the Innovation Advisory Council for Foundation Fighting Blindness and the Editorial Board of Jnal of Ocular Pharmacology and Therapeutics. Dr. Jayagopal holds a Ph.D. in Biomedical Engineering from Vanderbilt University and an M.B.A. from the Kelley School of Biness at Indiana University. An author on over 40 peer revied publications, Dr. Jayagopal has been awarded the Roche Key Contributor Award, the Dolly Green Special Scholar Award from Research to Prevent Blindness, and a Junior Faculty Award from the American Diabetes Association.- Ashwath Jayagopal在2021年至2024年2月期间担任Legacy OP的首席科学官。2019年至2021年，他在Kodiak Sciences Inc.担任Discovery Medicine执行董事，负责监督早期投资组合开发，并于2015年至2019年在罗氏担任眼科分子药理学和生物标志物负责人。他在罗氏的成就包括领导开展发现和IND支持研究的团队，包括FDA批准的视网膜血管疾病治疗药物Vabysmo（基因泰克商标），眼科首个双特异性抗体。在从事工业职业之前，Jayagopal博士曾在范德比尔特大学医学中心范德比尔特眼科研究所担任助理教授和美国国立卫生研究院资助的首席研究员。Jayagopal博士是视力和眼科研究协会（ARVO）的研究员，也是眼科药理学和治疗协会（AOPT）的主席。他在基金会对抗失明创新咨询委员会和眼药理学和治疗学杂志Jnal的编辑委员会任职。Jayagopal博士拥有范德比尔特大学生物医学工程博士学位和印第安纳大学凯利比尼斯学院工商管理硕士学位。Jayagopal博士是40多篇同行审查出版物的作者，曾被授予罗氏关键贡献者奖、研究预防失明的多利·格林特别学者奖，以及美国糖尿病协会颁发的初级教员奖。
- Ashwath Jayagopal served as the Chief Scientific Officer of Legacy Op from 2021 to February 2024. From 2019 to 2021, he served as Executive Director of Discovery Medicine at Kodiak Sciences Inc., where he supervised early stage portfolio development, and served as the Head of Molecular Pharmacology and Biomarkers in Ophthalmology at Roche from 2015 to 2019. His accomplishments at Roche included leadership of teams conducting discovery and IND enabling studies, including the FDA approved therapeutic for retinal vascular disease, Vabysmo (trademark of Genentech, Inc.), the first bispecific antibody in ophthalmology. Prior to his career in industry, Dr. Jayagopal served as an Assistant Professor and NIH funded Principal Investigator at the Vanderbilt Eye Institute, Vanderbilt University Medical Center. Dr. Jayagopal is a Fellow of the Association for Research in Vision and Ophthalmology (ARVO) as ll as a Fellow and the President of the Association for Ocular Pharmacology and Therapeutics (AOPT). He serves on the Innovation Advisory Council for Foundation Fighting Blindness and the Editorial Board of Jnal of Ocular Pharmacology and Therapeutics. Dr. Jayagopal holds a Ph.D. in Biomedical Engineering from Vanderbilt University and an M.B.A. from the Kelley School of Biness at Indiana University. An author on over 40 peer revied publications, Dr. Jayagopal has been awarded the Roche Key Contributor Award, the Dolly Green Special Scholar Award from Research to Prevent Blindness, and a Junior Faculty Award from the American Diabetes Association.